Kidney transplantation for end-stage renal disease after third allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
An 18-year-old man underwent allogenic bone marrow transplantation (BMT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ph+ALL relapsed 3 months after the first BMT, and the patient underwent a second BMT. However, Ph+ALL relapsed 4 months after the second BMT, and he received a haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) from his father. Molecular complete remission was confirmed 29 days after haplo-PBSCT. However, the patient needed dialysis for end-stage renal disease due to thrombotic microangiopathy 3 years and 2 months after haplo-PBSCT. He received a kidney transplantation from his father 7 years and 10 months after haplo-PBSCT, and got off dialysis after the kidney transplantation. Immunosuppressive therapy with methylprednisolone, tacrolimus, and mycophenolate mofetil was started for kidney transplantation, but the dose of immunosuppressive agents was reduced successfully without rejection soon after kidney transplantation. The patient has maintained long-term remission since the haplo-PBSCT, and his kidney function was restored by the kidney transplantation from his father.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 65(2024), 1 vom: 02., Seite 7-12 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Nishijima, Akihiko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allogeneic hematopoietic stem cell transplantation |
|---|
| Anmerkungen: |
Date Completed 12.02.2024 Date Revised 12.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11406/rinketsu.65.7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368192539 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368192539 | ||
| 003 | DE-627 | ||
| 005 | 20240213232913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11406/rinketsu.65.7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1291.xml |
| 035 | |a (DE-627)NLM368192539 | ||
| 035 | |a (NLM)38311391 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Nishijima, Akihiko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kidney transplantation for end-stage renal disease after third allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.02.2024 | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a An 18-year-old man underwent allogenic bone marrow transplantation (BMT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ph+ALL relapsed 3 months after the first BMT, and the patient underwent a second BMT. However, Ph+ALL relapsed 4 months after the second BMT, and he received a haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) from his father. Molecular complete remission was confirmed 29 days after haplo-PBSCT. However, the patient needed dialysis for end-stage renal disease due to thrombotic microangiopathy 3 years and 2 months after haplo-PBSCT. He received a kidney transplantation from his father 7 years and 10 months after haplo-PBSCT, and got off dialysis after the kidney transplantation. Immunosuppressive therapy with methylprednisolone, tacrolimus, and mycophenolate mofetil was started for kidney transplantation, but the dose of immunosuppressive agents was reduced successfully without rejection soon after kidney transplantation. The patient has maintained long-term remission since the haplo-PBSCT, and his kidney function was restored by the kidney transplantation from his father | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allogeneic hematopoietic stem cell transplantation | |
| 650 | 4 | |a Dialysis | |
| 650 | 4 | |a Kidney transplantation | |
| 650 | 4 | |a Renal failure | |
| 700 | 1 | |a Shingai, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohta, Akihito |e verfasserin |4 aut | |
| 700 | 1 | |a Suda, Kiyoko |e verfasserin |4 aut | |
| 700 | 1 | |a Omoto, Kazuya |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshioka, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kurosawa, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Hino, Yutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Senoo, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Igarashi, Aiko |e verfasserin |4 aut | |
| 700 | 1 | |a Oshikawa, Gaku |e verfasserin |4 aut | |
| 700 | 1 | |a Hamamura, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Toya, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Najima, Yuho |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Haraguchi, Kyoko |e verfasserin |4 aut | |
| 700 | 1 | |a Okuyama, Yoshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohashi, Kazuteru |e verfasserin |4 aut | |
| 700 | 1 | |a Doki, Noriko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 65(2024), 1 vom: 02., Seite 7-12 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2024 |g number:1 |g day:02 |g pages:7-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.65.7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2024 |e 1 |b 02 |h 7-12 | ||